SCHEMBL5166956

SCHEMBL5166956

COC(=O)Cc1cccc(-c2ccc(CNS(=O)(=O)c3ccccc3OC)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 3/20 0.51
ACLY P53396 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
BRD4 O60885 3/20 0.46
BRD2 P25440 1/20 0.46
BRD3 Q15059 1/20 0.46
FABP4 P15090 2/20 0.46
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
CNR1 P21554 1/20 0.46
HPGD P15428 1/20 0.45
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163905 0.81 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1ACLYL3MBTL1BRD4
SCHEMBL5166693 0.80 NR3C2 (0.57) SMN1; SMN2ALDH1A1ACLYL3MBTL1BRD4
SCHEMBL1929079 0.76 SLC7A5 (0.57) SMN1; SMN2ALDH1A1HPGDLMNAMAPT
SCHEMBL5167268 0.75 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1L3MBTL1BRD4BRD2
SCHEMBL5164007 0.75 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1ACLYL3MBTL1BRD4
SCHEMBL3357160 0.75 SLC7A5 (0.56) SMN1; SMN2ALDH1A1HPGDLMNAMAPT
SCHEMBL7031826 0.74 HTR7 (0.63)
SCHEMBL5166003 0.74 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1L3MBTL1FABP4CYP1A2
SCHEMBL13460869 0.74 SLC7A5 (0.49) SMN1; SMN2ALDH1A1HPGDMAPTPKM
SCHEMBL5167263 0.73 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1L3MBTL1BRD4BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765332-A2 TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-03-28 EP disclosed
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed
WO-2006009876-A2 TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases PTPA, PTPN1, PTPRS SMN1; SMN2 3478/4885ALDH1A1 3296/4885ACLY 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.